Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...
Publications
10 shownPembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks...
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rat...
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Purpose To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of overall survi...
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
2 and 10 mg/kg Q3W, respectively, over control (P<0.00001 for both comparisons). The 6-month PFS rate was 34% (95% CI 27%-41%) and 38% (95% CI 31%45%) for pembrolizumab 2 and 10...
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Abstract Purpose: Immunotherapeutic agents produce antitumor effects by inducing cancer-specific immune responses or by modifying native immune processes. Resulting clinical res...
Frequent Co-Authors
Researcher Info
- h-index
- 10
- Publications
- 10
- Citations
- 36,647
- Institution
- Angeles Clinic and Research Institute
External Links
Identifiers
- ORCID
- 0000-0002-8238-4655
Impact Metrics
h-index
10
h-index: Number of publications with at least h citations each.